Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazpilodemab in T2DM and NAFLD
NCT03060538Phase 1Completed
- Sponsor
- Genentech
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) comparing Multiple Ascending Dose BFKB8488A with Placebo (2 arms). Primary endpoint: Percentage of Participants with Adverse Events at 18 weeks. Started Mar 2017; status: completed.
02
Drugs
fazpilodemab
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03060538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060538.